The Board of Oslo Cancer Cluster Incubator has extensive oncology business knowledge and experience with commersialization of research and early phase company development.
Ketil F. Widerberg, MBA, is General Manager of Oslo Cancer Cluster and Chairman of the Board of Oslo Cancer Cluster Incubator.
He builds on a long experience in realizing new projects within oncology in the biopharmaceutical company Photocure ASA in collaboration with academic institutions and international commercial partners.
Ketil has a broad operational experience ranging from explorative project management to being responsible for business development.
Widerberg’s educational background spans from preclinical medical school to management studies. He also holds a MBA from the University of Cambridge.
Hanne Mette D. Kristensen
Hanne Mette D. Kristensen is an independent consultant. Kristensen has a strong track record in commercialization of research and early phase company development, with over 20 years of experience. She has a broad national and international network.
Kristensen was CEO of Targovax until 2015. Before that she was VP Oncology in Bio-Medical Innovation. Before that she was CEO of Diatec Monoclonals. She has also been a scientist at the Institute of Immunology, Oslo University Hospital. She holds an M.Sc. in biochemistry from the University of Oslo, and a Master in Technology Management (MTM) from NTNU, NHH and MIT Sloan School of Management.
Ann-Kristin Hageløkken has more than 25 years experience within product/business development and marketing from the banking/telecommunication and biotechnology industries. From 2002 to 2010 Hageløkken was the CEO of Bioparken AS, which aims to identify, develop and bring inventions and business ideas to the market.
Today she is senior adviser in Siva SF. In addition she holds several Board positions. Hageløkken is a bioengineer from Oslo University College, a business graduate from BI and she holds a Master of Management. She is a Norwegian citizen and residence in Oslo, Norway.
Anders Tuv is Investment Director of The Norwegian Radium Hospital Research Foundation. Experienced investment, financial and business development
professional with broad experience from biotech and healthcare.
Anders is currently member of the board in Nextera, Vaccibody and Oslo Cancer Cluster Incubator. He is also chairman of the board in Sophies Minde Ortopedi AS, and part of nomination committees in PCI Biotech, Targovax and Oslo Cancer Cluster SA.
Tron Sanderud is the CEO at both Oslo Cancer Cluster Innovation Park AS and Utstillingsplassen Eiendom AS.
Sanderud is an attorney with a law exam from the University of Oslo in 1979, and he was a partner in a law firm 1985 to 2011. He has mainly been working as a business lawyer, especially in the field of real estate and property development.
Tron Sanderud also has broad experience as board member.
Knut Allum, MBA is Vice President Business Development & Marketing for Inven2 AS.
The last 20 years Knut has served as CEO for Unified Messaging Systems AS (Global Population Alert Solutions), Vindfang ASA (alliance of 12 Nordic IT and consulting companies), Norwegian Interactive Architects AS (incubator), AheadAdvice AS and Geelmuyden Kiese Nye Medier AS.
Knut also has experience from global offshoring, business development and process harmonization for organizations such as Det Norske Veritas AS, EDB Business Partner ASA and Telenor ASA.
Knut is currently member of the board in Epiguard AS, CDE Holding and Normetrix AS. He has previously been a member of the board of UMS Denmark and India, Aheadadvice AS, Autonomy Nordic, Transport Online Norway, Denmark and Germany.